E-LIB Suche - Ergebnisse für: Iurlo, A.

1

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Ver..:

Palandri, F. ; Auteri, G. ; Abruzzese, E....
Annals of Hematology. 103 (2024) 6 - p. 1931-1940 , 2024

Link: https://doi.org/10.1007/..

2

Treatment discontinuation following low-dose TKIs in 248 ch..:

Iurlo, A. ; Cattaneo, D. ; Consonni, D....
Frontiers in Pharmacology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

3

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONS..:

Palandri, F. ; Bartoletti, D. ; Breccia, M....
HemaSphere. 6 (2022) - p. 900-901 , 2022

Link: https://doi.org/10.1097/..

4

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOU..:

Vannucchi, A. ; Mesa, R. ; Gerds, A....
HemaSphere. 6 (2022) - p. 940-941 , 2022

Link: https://doi.org/10.1097/..

5

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PAT..:

Mora, B. ; Guglielmelli, P. ; Kuykendall, A....
HemaSphere. 6 (2022) - p. 885-886 , 2022

Link: https://doi.org/10.1097/..

6

S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILIT..:

Mancini, M. ; De Santis, S. ; Monaldi, C....
HemaSphere. 6 (2022) - p. 53-54 , 2022

Link: https://doi.org/10.1097/..

7

Covid-19 in Philadelphia-negative myeloproliferative neopla..:

Breccia, M. ; Piciocchi, A. ; Messina, M....
Leukemia. 36 (2022) 10 - p. 2548-2550 , 2022

Link: https://doi.org/10.1038/..

8

P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN..:

Barbui, T. ; Carobbio, A. ; Masciulli, A....
HemaSphere. 6 (2022) - p. 899-900 , 2022

Link: https://doi.org/10.1097/..

9

P697: PONATINIB IN A REAL-LIFE SETTING: A RETROSPECTIVE ANA..:

Breccia, M. ; Olimpieri, P. P. ; Celant, S....
HemaSphere. 6 (2022) - p. 592-593 , 2022

Link: https://doi.org/10.1097/..

10

P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REP..:

Efficace, F. ; Cottone, F. ; Yanez, B....
HemaSphere. 6 (2022) - p. 1587-1588 , 2022

Link: https://doi.org/10.1097/..

11

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PA..:

Cattaneo, D. ; Galli, N. ; Bucelli, C...
HemaSphere. 6 (2022) - p. 908-909 , 2022

Link: https://doi.org/10.1097/..

12

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MM..:

Verstovsek, S. ; Vannucchi, A. ; Gerds, A....
HemaSphere. 6 (2022) - p. 96-97 , 2022

Link: https://doi.org/10.1097/..

13

P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID..:

Palandri, F. ; Bartoletti, D. ; Elli, E. M....
HemaSphere. 6 (2022) - p. 901-902 , 2022

Link: https://doi.org/10.1097/..

14

P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATM..:

Castagnetti, F. ; Bocchia, M. ; Abruzzese, E....
HemaSphere. 6 (2022) - p. 593-594 , 2022

Link: https://doi.org/10.1097/..

15

Recovering from chronic myeloid leukemia: the patients' per..:

Graffigna, G. ; Cecchini, I. ; Breccia, M....
Quality of Life Research. 26 (2017) 10 - p. 2739-2754 , 2017

Link: https://www.jstor.org/st..